Physician profile
Robert W Jones
NPI 1245454404
$7,220.41
in general payments reported to CMS, 2019-2025
27 companies · $3,977 in 2025
The $3,977 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $68.21 · 2021: $148 · 2022: $314 · 2023: $941 · 2024: $1,351 · 2025: $3,977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,733 · Consulting Fee: $1,300 · Education: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,732.62 |
| Consulting Fee | $1,300.00 |
| Education | $236.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,750.75 | 2019-2025 | Bimzelx |
| Abbvie INC. | $1,020.24 | 2019-2025 | |
| Genzyme Corporation | $698.34 | 2019-2025 | |
| Pfizer INC. | $628.38 | 2019-2025 | |
| Janssen Biotech, INC. | $585.76 | 2023-2025 | Tremfya, Simponi, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $517.35 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $249.72 | 2019-2025 | |
| Incyte Corporation | $245.97 | 2024-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $211.62 | 2019-2025 | Nemluvio |
| Amgen INC. | $204.95 | 2023-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $170.45 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $154.62 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Sun Pharmaceutical Industries INC. | $134.99 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $116.11 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $85.20 | 2023-2025 | Adbry |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Dermavant Sciences, INC. | $71.29 | 2023-2024 | Vtama |
| Botanix Sb INC | $64.94 | 2025 | Sofdra |
| Organon LLC | $47.29 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.97 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.00 | 2023 | Cyltezo |
| Ethicon US, LLC | $27.06 | 2024 | Stratafix, Dermabond Prineo |
| Mayne Pharma Commercial LLC | $20.85 | 2025 | |
| Medimetriks Pharmaceuticals, INC. | $18.42 | 2025 | Clindacin Etz |
| Almirall LLC | $16.07 | 2019 | |
| Genentech USA, INC. | $15.91 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.